Fluorometholone
As of the edition of 20 October 2026, Fluorometholone is a small molecule: marketed, first approved in 1972 (CA); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1984
- Kind
- Small molecule
- Brand name
- Oxylone
- First approved
- 31 December 1972 (CA)
- Approvals on record
- 12 in 5 regions
- Holder of the most recent approval
- AbbVie; 6 holders in all
- Registered trials
- 9, 1 stopped early
- Disease areas
- Eye; Infections; Cancer; Digestive system; Hormones; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Fluorometholone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 3 | 0 | 1 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant and Later holder | 1972 to now |
| Alcon | Later holder | 1986 to now |
| Harrow Eye | Acquired holder | 2023 to now |
| Pfizer | Applicant |